Navigation Links
Scripps Florida scientists awarded $1.5M to fight major water and food parasites
Date:10/28/2008

This award includes $1.5 million granted to the laboratory of William Roush, Ph.D., of Scripps Florida, a division of The Scripps Research Institute. Other participants in the consortium are University of California, San Diego (UCSD), University of California, San Francisco (UCSF), and University of Washington.

Roush, executive director of the Scripps Florida Translational Research Institute Medical Chemistry division and professor in the Scripps Research Department of Chemistry, is a co-principal investigator for the project.

"Amebiasis and giardia are serious diseases that affect thousands of people in the United States and throughout the world," Roush said. "Our work, along with others in the consortium, is to develop new small molecule inhibitors that will target specific proteases that play a critical role in the lifecycle of these parasites and bring these agents to the pre-clinical development stage."

It has been estimated that up to 10 percent of the world's population is infected with Entamoeba histolytica, the one-celled parasite that causes amoebiasis. The parasite Giardia lamblia is the most common cause of water-borne protozoal infection in the United States, with more than 20,000 cases each year.

Various laboratory studies have noted that both parasites have developed resistance to antibiotic treatment, setting off alarm bells within the health care community.

"Because of the rise in parasitic resistance, the development of more effective treatments has become even more critical, especially if we want to prevent future outbreaks," Roush said. "This funding helps bring together the expertise of four major laboratories that will focus on finding a solution to this serious threat to human health.

Attractive Targets

Roush's laboratory is looking at cysteine proteases, which are common in protozoan parasites and are involved in nutrition and immune system evasion. What makes these proteases attractive as therapeutic targets is that they are found in a number of different parasites, and that synthetic inhibitor libraries have already been developed against this enzyme family.

As a result, a wealth of inhibitor leads already exist, many of which have been subject to extensive pharmacokinetic and safety studies; for example cysteine protease inhibitors have already demonstrated potent anti-trypanosomal effects.

"This family of enzymes is well known biochemically and structurally," Roush said, "and we understand the relationship between structure and function that involves active site specificity. Our laboratory has used this information to help design new inhibitors that attack targets critical to invasive Entamoeba histolytica."

The new inhibitor designed by Roush's laboratory attacks the EhCP1 (Entamoeba histolytica cysteine proteinase), which is believed to be a virulence factor of this parasite.

"We have designed a compound that has very good properties as an inhibitor of this particular protease," Roush said. "When you kill this enzyme, you kill the parasite's ability to infect human tissue. In animal models, this molecule behaves beautifully in that capacity. Unfortunately, it's not an orally bioavailable compound, so right now we're working to optimize it to make it orally available."


'/>"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
Source:Eurekalert

Related biology news :

1. Scripps research team sheds light on immune system suppression
2. Scripps research team solves structure of beneficial virus
3. Oceans on the precipice: Scripps scientist warns of mass extinctions and rise of slime
4. Scripps scientists will assess Beijing Olympics air pollution control efforts
5. Scripps study sets high economic value on threatened Mexican mangroves
6. Scripps research scientists reveal key structure from ebola virus
7. Scripps Research Institute awarded patent for remarkable chemical technology
8. Scripps Oceanography Research pegs ID of red tide killer
9. Fishing throws targeted species off balance, Scripps study shows
10. Bright lights: Mystery of glowing antibody solved by Scripps research scientists
11. Scripps expedition provides new baseline for coral reef conservation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... 2017 Report Highlights The global ... $8.3 billion in 2016 at a compound annual growth ... Report Includes - An overview of the global market ... data from 2015 and 2016, and projections of compound ... the market on the basis of product type, source, ...
(Date:2/7/2017)... BEACH, New York , February 7, 2017 /PRNewswire/ ... known as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" ... identity management and electronic transaction processing services, is pleased ... reorganization of the Company. Effective January 31, ... of the Board of Directors, CEO and President.  An ...
(Date:2/3/2017)... A new independent identity strategy consultancy firm ... . Designed to fill a critical niche in technical ... partners Mark Crego and Janice Kephart ... identity expertise that span federal governments, the 9/11 Commission, ... combined expertise has a common theme born from a ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... 23, 2017 /PRNewswire/ - The Fight Against Cancer Innovation ... (OICR) are pleased to report that Fusion Pharmaceuticals Inc. ... Johnson & Johnson Innovation – JJDC, Inc. (JJDC) as ... HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well ... ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life ... product line of oncolytic vaccinia viruses for virotherapy ... as part of Genelux,s proprietary, vaccinia virus-based technology ... excited to enter into a partnership with Genelux ... oncolytic vaccinia viruses for use in research," said ...
(Date:2/23/2017)... ... , ... Today, researchers can fast-track sample collection and analysis ... biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. With the addition ... insulin and other relevant biomarkers can be extensively studied through a non-invasive sample ...
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017 /PRNewswire/ ... and Beyond Type 1, a not-for-profit advocacy and education ... announced a grant from Beyond Type 1 to support ... 1 and other insulin-requiring diabetes.  For ... stem cell-derived cell replacement therapies with a focus on ...
Breaking Biology Technology: